Patents by Inventor Sophie Siberil

Sophie Siberil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors
    Patent number: 7790399
    Abstract: The present invention relates to a method for the production and the selection of human or chimæric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB/CD32).
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: September 7, 2010
    Assignees: Laboratoire Francais du Fractionnement et des Biotechnolgies (LFB), Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Dominique Bourel, Christophe De Romeuf, Sophie Siberil, Wolf Herman Fridman, Jean-Luc Teillaud, Nicolas Bihoreau, Emmanuel Nony
  • METHOD FOR PREPARING ANTIBODIES SELECTIVE FOR ACTIVATING FC RECEPTORS
    Publication number: 20090029393
    Abstract: The present invention relates to a method for preparing an antibody selective for activating antibody Fc region receptors (FcRs) comprising an ITAM motif or motifs (immunoreceptor tyrosine-based activation motif), comprising the steps of obtaining monoclonal antibodies from a hybridoma, from a heterohybridoma or from any animal, plant or human cell line, replacing each of the His 310 and His 435 residues (Cabat numbering) of the Fc region of said antibody with a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, and then selecting the antibodies for which the binding to inhibitory FcRs comprising ITIM motifs (immunoreceptor tyrosine-based inhibition motif) is decreased by at least 30%, preferably by at least 50%, 70%, 80% or else by at least 90% relative to the same antibody having a natural Fc region.
    Type: Application
    Filed: December 15, 2006
    Publication date: January 29, 2009
    Applicant: LFB Biotechnologies
    Inventors: Jean-Luc Teillaud, Sylvie Jorieux, Sophie Siberil, Renee Menez, Enrico Stura, Frederic Ducancel
  • Therapeutic products with enhance ability to immunomodulate cell functions
    Publication number: 20070135621
    Abstract: The present invention relates to a method for the production and the selection of human or chimaeric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB/CD32).
    Type: Application
    Filed: April 5, 2004
    Publication date: June 14, 2007
    Applicants: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Dominique Bourel, Christophe De Romeuf, Sophie Siberil, Wolf Fridman, Jean-Luc Teillaud, Nicolas Bihoreau, Emmanuel Nony